Participants are randomly assigned to receive either the study drug at two possible doses or the placebo, and neither the participants nor the study staff know which treatment is given. Over 52 weeks, participants attend regular clinic visits where safety is checked through physical exams, vital signs, weight measurements, and questionnaires about mood. Cognitive and functional abilities are measured using the clinical dementia rating – sum of boxes, a score that reflects the severity of dementia, and the integrated Alzheimer’s disease rating scale, a test that looks at memory and daily tasks. Blood samples are taken to assess proteins linked to Alzheimer’s, such as p-Tau217 (a form of tau protein), amyloid β-protein Aβ40 and Aβ42 (building blocks of plaque), as well as markers of nerve damage (neurofilament light chain) and brain inflammation (glial fibrillary acidic protein). Brain imaging includes a size‑measuring scan called volumetric magnetic resonance imaging and a special scan that visualizes amyloid plaques known as amyloid positron emission tomography. All data are collected to evaluate whether the medication is safe and whether it helps preserve thinking and daily abilities.

The purpose of the trial is to find out whether adding pramipexole to the usual treatment can reduce anhedonia more effectively than placebo over a period of six weeks. Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the study staff will know which is which (this is called a double‑blind design). Throughout the study, participants will visit the clinic several times for brief checks, and they will keep taking the tablets every day.

After the initial six‑week period, participants may be offered an open‑label follow‑up where everyone receives the active medication for up to 15 additional weeks. During the trial, simple tools such as questionnaires about mood and activity levels will be used, and some participants may undergo brain imaging with fMRI to explore how the drug affects brain activity. Safety will be monitored by asking about side effects and checking for any signs of mood changes.

People in the study are placed into one of two groups. One group has the blood flow checked with indocyanine green fluorescence imaging, which means the dye is used so the surgeon can see how blood moves through the flap. The other group is checked with standard clinical assessment, which means the usual way of judging the flap during surgery. After the operation, the flap is followed for a short time to see how it heals and whether any further treatment is needed.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

Participants are divided into two groups based on their blood test results. For those who do not have detectable tumor DNA in their blood, the study compares a 6-month course of capecitabine alone to a 3-month course of oxaliplatin combined with capecitabine. For those who do have detectable tumor DNA, the study compares a 6-month course of fluorouracil, irinotecan, oxaliplatin, and calcium folinate to a 6-month course of fluorouracil, oxaliplatin, and calcium folinate. Calcium folinate is a substance used to help the other medications work more effectively.

During the study, the effectiveness of these treatments is monitored by looking at disease-free survival, which is the length of time a patient lives without any signs or symptoms of the cancer returning. The study also tracks overall survival and any side effects caused by the medications, such as neurotoxicity, which is damage to the nerves that can cause issues like tingling or numbness. The course of the study involves receiving the assigned medication through pills or an intravenous infusion, which is a method of delivering medicine directly into a vein through a tube.

The treatment involves gene therapy, which is a method used to introduce genetic material into cells to help the body produce the missing clotting proteins. Participants in this study will be monitored over a long period of time to observe how the body responds to these treatments. This includes tracking the level of clotting factor, which is the protein responsible for stopping bleeding, and checking for any potential issues such as thromboembolic events, which are blood clots that can travel through the bloodstream, or changes in liver health.

The purpose of the trial is to assess how practical and well‑tolerated the alternate‑day iron supplement is, how consistently participants can follow the dosing schedule, and how accurately the screening tool IRON-5 can identify iron deficiency.

During the study, each girl will take the assigned tablet on alternate days for several weeks and will attend a few clinic visits where blood samples are drawn to check iron levels and related nutrients. She will also complete brief questionnaires about diet, menstrual patterns, fatigue and overall well‑being. All information collected will help determine the safety and ease of use of the supplement and the performance of the screening tool.

During the course of the study, the way the body processes the medication, known as pharmacokinetics, and the drug’s effects on the body, known as pharmacodynamics, will be observed. Researchers will also look at NfL, which is a specific protein found in the blood and cerebrospinal fluid—the clear liquid that surrounds the brain and spinal cord—that can indicate nerve cell damage. The study will monitor how the disease progresses and look at how the treatment affects physical functions and survival over a period of time.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

During the trial, participants will take the KET01 tablets in addition to their usual antidepressant therapy. The course of the study involves regular check-ins to monitor how the combination of medications affects mood and overall well-being over a period of several weeks.

During the trial, participants will be assigned to receive either rituximab or a placebo. The study will last for 48 weeks. While receiving the assigned treatment, the progress of the lung condition and the effectiveness of the medication will be monitored to see if it helps prevent the decline of the amount of air the lungs can hold.

Participants in the study will receive either AZD5148 or a placebo. The medication will be given as an intravenous infusion, which means it is delivered directly into a vein through a needle or tube. This treatment is administered alongside standard care, which includes regular antibacterial drugs used to treat the current infection. During the study, individuals will be monitored to see if the infection returns within a specific period of time.

The purpose of this study is to find out whether two different weekly doses of the under-the-skin treatment produce similar levels of the protective protein in the blood compared to the standard doses of the into-the-vein treatment. The study will also look at how safe these treatments are and how well they are tolerated by patients. During the study, participants will first receive the into-the-vein treatment for eight weeks, and then they will switch to receiving the under-the-skin treatment for another eight weeks. Throughout this time, blood samples will be taken regularly to measure the amount of the protective protein in the blood and to see how the body processes the medication. The study will also monitor any side effects that may occur and check lung function to see how well the treatment is working.

Participants in this study will be people between 18 and 80 years old who have been diagnosed with Alpha-1 Antitrypsin Deficiency through genetic testing and have certain breathing difficulties. They may be new to this type of treatment or may already be receiving it, but they will need to stop any other similar treatments during the study. The study will track various measurements including heart rate, blood pressure, breathing rate, temperature, and lung function tests to ensure the safety of participants. Blood tests will also be done to check for any immune system reactions to the treatment and to monitor overall health.

The purpose of the study is to find out if atorvastatin can prevent the development of active Graves ophthalmopathy in patients who have just been diagnosed with Graves’ disease. Participants will take atorvastatin tablets by mouth for a period of 12 months. The maximum daily dose will be 40 milligrams. During the study, patients will be monitored at several time points over 18 months to check if they develop eye problems and to measure the activity level of any eye inflammation using a scoring system. The study will also look at how the treatment affects quality of life and measure certain antibodies in the blood that are related to the disease.

Throughout the study period, researchers will collect information about whether patients need additional treatments for eye problems, such as corticosteroids or other medications. Blood samples will be analyzed to look for biological markers that might help predict who will respond well to the treatment. The study will also examine genetic differences between people who respond to atorvastatin and those who do not. Patients will complete questionnaires about their quality of life at the beginning of the study, after 12 months, and after 18 months to see how the treatment affects their daily living and well-being.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The purpose of this study is to evaluate the long-term effect of tozorakimab in reducing severe flare-ups of the lung disease in people who used to smoke. The study will also look at how safe the medication is when used over a longer period of time. This is an extension study, which means it is designed for people who have already participated in earlier studies of the same medication and completed their treatment without stopping early.

Participants who join this study will continue receiving the same type of treatment they were on in the previous study for up to 52 weeks. They will attend regular clinic visits where doctors will check their lung function, ask about any breathing problems or flare-ups, and monitor for any side effects. The study will track how often participants experience severe flare-ups that require emergency room visits or hospital stays, and will measure how long it takes before these serious episodes occur. Blood samples may be collected to measure the amount of medication in the body and to check how the immune system responds to the treatment.

Participants in this study must have been diagnosed with fibromyalgia within the past two years and must have significant pain levels. They must also have specific antibodies in their blood that are associated with fibromyalgia. These antibodies are proteins made by the immune system that may be causing some of the pain symptoms. The study will measure how much pain decreases sixteen weeks after participants receive the rituximab treatment. Rituximab will be given through a tube inserted into a vein, which is called an infusion. The treatment period will last for one day, and participants will be followed for sixteen weeks after receiving the medicine.

During the study, researchers will measure pain levels using a scale where participants mark how much pain they feel. They will also use questionnaires to understand how fibromyalgia affects daily life and whether participants feel their condition has improved. The study will also look at changes in the antibodies in the blood to see if there is a connection between these antibodies and pain levels. The entire study is expected to run from early 2026 to early 2027.

The purpose of the study is first to find the right dose of izalontamab brengitecan to use, and then to see how well this medicine works compared to platinum-based chemotherapy in people whose cancer has gotten worse during or after treatment with immunotherapy. The study is designed for people who have already received immunotherapy treatment and whose cancer has continued to grow or spread despite this treatment. Participants in this study must be able to receive platinum-based chemotherapy and should not have had more than two previous types of treatment for their cancer that has spread.

The study will be done in two phases. In the first phase, researchers will determine the best dose of izalontamab brengitecan by looking at how safe it is and how well it works. In the second phase, participants will be randomly assigned to receive either izalontamab brengitecan or platinum-based chemotherapy, and the two treatments will be compared. The study will measure how long it takes for the cancer to get worse, how long participants live, how many people respond to treatment, and how long those responses last. The study will also look at how the treatments affect quality of life.

During the study, patients will receive treatment and then be carefully monitored to see if their cancer has completely disappeared. The monitoring will be done using different methods including magnetic resonance imaging, which is a type of scan that creates detailed pictures of the inside of the body, along with clinical examinations where a doctor checks the patient, and endoscopic examinations where a flexible tube with a camera is used to look inside the rectum. The study aims to find out whether it is possible to save the rectum by watching and waiting after the initial treatment instead of immediately performing surgery.

The study will also look at other important outcomes such as whether the cancer comes back in the same area, whether the cancer spreads to other parts of the body, how long patients survive, whether the rectum can be preserved without surgery, and what side effects or complications occur from the treatment. Additionally, the study will examine how the treatment affects daily life including urinary function, sexual function, bowel function, and whether patients need a stoma, which is an opening created surgically for waste to leave the body.

The purpose of the study is to find out if using less iodine contrast during the procedure by using carbon dioxide gas instead when possible can reduce kidney problems after the surgery compared to the usual approach. Kidney problems can sometimes happen after this type of procedure because the contrast material can affect how the kidneys work. The study will compare two different strategies: one that tries to use carbon dioxide for imaging whenever possible to reduce the amount of iodine contrast needed, and one that uses the standard amount of iodine contrast.

During the study, patients will be randomly assigned to receive one of these two imaging strategies during their planned procedure. The doctors will monitor kidney function by checking blood tests and urine output after the surgery to see if there are any signs of kidney injury. Patients will be followed for up to three years after the procedure with regular check-ups, imaging scans, and questionnaires about their quality of life and recovery. The study will also track other important outcomes such as the success of the surgery, any complications that occur, survival rates, and changes in kidney function over time.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

The purpose of the study is to find out if adding Saruparib to the standard treatment of radiotherapy and androgen deprivation therapy can help men with this type of prostate cancer live longer without the cancer spreading to distant parts of the body compared to placebo. The study will measure how long participants remain free of distant spread of cancer, which is called metastases-free survival, and will also look at overall survival and other measures of how well the treatment works. During the study, participants will receive the study medication in tablet form taken by mouth, and they will need to have various scans including computed tomography or magnetic resonance imaging, bone scans, and prostate-specific membrane antigen-positron emission tomography scans to check for any signs of cancer spread.

Participants will be randomly assigned to receive either the active study medication or placebo in addition to their standard treatment, and neither the participants nor their doctors will know which treatment they are receiving during the study. The study requires tissue samples from the prostate cancer to confirm the presence of the BRCA gene mutation before enrollment. Throughout the study, participants will be monitored for how the treatment affects their cancer, their overall health, and their quality of life through questionnaires about symptoms and daily functioning. Blood samples will also be collected to measure the levels of the study medication in the body and to understand how it works.

The purpose of this study is to evaluate the long-term safety and how well mezagitamab works in adults who have already participated in previous studies with this medicine and completed those studies. The study will look at whether the treatment causes any unwanted effects over a longer period of time and whether it continues to help maintain platelet counts at safe levels. The study will also examine how long the positive effects on platelet counts last, whether people need fewer other medicines for their condition, and whether they need less emergency treatment for low platelet counts.

During the study, participants will receive mezagitamab through subcutaneous injection, which means the medicine is injected into the tissue just under the skin. The treatment can continue for up to 104 weeks. Throughout the study, doctors will monitor participants for any side effects and measure how the body responds to the treatment by checking platelet counts and other blood tests. The study will also check how the medicine moves through the body and whether the body develops any reaction against the medicine over time.

The purpose of this study is to evaluate the long-term safety and how well GSK4527226 works in people with early Alzheimer’s Disease. This is an extension study, which means it follows people who have already completed a previous study with the same medication. The study will look at any side effects that occur and will pay special attention to certain brain-related imaging findings that can sometimes happen with this type of treatment. These findings are monitored using brain scans to ensure participant safety throughout the study.

Participants will continue receiving GSK4527226 for up to 104 weeks, which is about two years. During this time, they will attend regular clinic visits where doctors will check their health and monitor for any unwanted effects. The study will also measure changes in memory, thinking abilities, and daily functioning using various assessments and questionnaires. A study partner, such as a family member or close friend who spends regular time with the participant, will need to attend some visits to provide information about how the participant is managing daily activities. All participants in this study will receive the active medication, as this is not a comparison study with placebo.

The purpose of the study is to find out if Mezagitamab can help increase the number of platelets in the blood and keep them at a safe level over time in adults with this condition. The study will also look at whether the medicine is safe and how well it works compared to placebo. People taking part may continue some of their current treatments for this condition during the study if their doctor thinks it is appropriate. These might include medicines that help the body make more platelets or certain steroid medicines.

During the study, participants will receive injections of either Mezagitamab or placebo for up to 24 months. Regular blood tests will be done to measure platelet levels, and doctors will check for any bleeding problems or side effects. The study will measure how many people achieve and maintain a platelet count that is considered safe, which is at least 50,000 platelets per microliter of blood. Participants will also be asked about their symptoms and quality of life throughout the study.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The main purpose of this research is to determine if izalontamab brengitecan works better than standard chemotherapy treatments in patients who cannot receive certain types of immunotherapy treatments (anti-PD1/PD-L1). The study will measure how long patients live without their cancer getting worse and their overall survival time. During treatment, some patients may also receive pegfilgrastim, a supportive care medicine that helps the body make white blood cells.

The medications will be given in different ways – some through an intravenous infusion directly into a vein, while others, like capecitabine, are taken by mouth as tablets. The study will continue for several years to gather information about how well the treatments work and how safe they are for patients.

The purpose of this research is to determine if Datopotamab deruxtecan combined with Durvalumab works better than currently available treatments in preventing the cancer from returning after surgery. The medications being studied are given through an intravenous line directly into the bloodstream, except for Capecitabine and Mycophenolate mofetil which are taken as tablets by mouth.

During the study, participants will be randomly assigned to receive either Datopotamab deruxtecan alone, Datopotamab deruxtecan with Durvalumab, or one of the standard treatment options. The study will monitor how long patients remain free of cancer after starting treatment and track their overall health and well-being throughout the study period.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The research aims to determine if rilzabrutinib can help maintain stable blood levels in people with warm autoimmune hemolytic anemia. During the study, participants will receive either rilzabrutinib tablets or placebo tablets. The maximum daily dose of rilzabrutinib will be 800 mg, and the treatment period will last for 224 weeks.

The study will measure several aspects of the treatment’s effects, including changes in hemoglobin levels (a protein in red blood cells that carries oxygen throughout the body), changes in fatigue levels, and how quickly the treatment works. The study will also track how well participants feel, including their ability to breathe comfortably, and monitor any side effects that may occur during treatment.

The purpose of this research is to determine how well ibuzatrelvir works when used alone or combined with remdesivir in treating COVID-19 symptoms and reducing the amount of virus in people with weakened immune systems. The study includes people who have received organ transplants, those with blood cancers, individuals who have received certain cancer treatments, or those taking medications that affect their immune system.

During the study, participants will receive the study medication for up to three days. They will be monitored for changes in their COVID-19 symptoms and the amount of virus in their body. The study will track whether participants need emergency care, hospital treatment, or experience other health problems related to COVID-19. The total study period is 38 days, during which participants will have regular check-ups to monitor their health and any side effects.

The study will compare VHB937 with placebo over a period of 72 weeks, followed by an extension period. During the study, participants will receive regular infusions of either the study medication or placebo. The study will include people who have early Alzheimer’s Disease, including those with Mild Cognitive Impairment due to Alzheimer’s.

Throughout the study, doctors will monitor changes in participants’ ability to think and perform daily activities. They will use various tests to measure memory and thinking skills, including the Clinical Dementia Rating scale. Participants will undergo regular health checks, including brain MRI scans, to ensure safety. Some participants may continue taking their regular Alzheimer’s medications during the study if they were already using them before joining.

The study examines whether adjusting tamoxifen doses (10 mg, 20 mg, or 40 mg daily) based on individual patient factors leads to better long-term use of the medication compared to the current standard treatment of 20 mg daily. Patients will be randomly assigned to either receive the standard fixed dose or a personalized dose. The treatment will continue for up to 5 years, during which patients will need to take tablets daily.

Throughout the study, doctors will monitor how well patients tolerate the medication and track various aspects of their health, including quality of life and any return of cancer. Blood samples will be collected to measure how the medication is working in the body. The study will also look at the density of breast tissue on mammograms and evaluate the overall effectiveness of the treatment.

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

The treatment being studied is the Comirnaty Omicron XBB.1.5 COVID-19 mRNA Vaccine, which is a type of vaccine that uses a small piece of genetic material called mRNA to help the body recognize and fight the virus that causes COVID-19. This vaccine is given as an injection. Some participants in the study will receive this vaccine, while others will receive a 0.9% Sodium Chloride solution, which is a simple saline solution used as a placebo.

The study will follow the children over time to see if the vaccine helps in reducing the development of islet autoantibodies or Type 1 Diabetes. The main goal is to measure the time it takes for these conditions to develop after the children are randomly assigned to receive either the vaccine or the placebo. The study will continue until 2029, allowing researchers to gather enough information to understand the vaccine’s impact on preventing Type 1 Diabetes in children with a high genetic risk.

Participants in the study will receive the Gardasil 9 vaccine, which is given as an injection. The study will monitor how many women receive the vaccine and how well they follow the vaccination schedule. The goal is to see if this combined approach of vaccination and screening can reduce the number of HPV infections and, ultimately, cases of cervical cancer in the population.

The study will take place over several years, with the aim of understanding the long-term benefits of this approach. By focusing on young women who are due for cervical cancer screening, the study hopes to provide valuable insights into the effectiveness of combining vaccination with regular health checks in preventing HPV-related diseases.

The study is divided into two parts. In the first part, healthy volunteers will receive the NEP-1 injection to determine the right dose and timing for examining lymph nodes using the NanoEcho Imaging Device. In the second part, patients with rectal cancer will receive the same treatment to confirm the findings from the first part. The study aims to see how well the device can detect changes in the lymph nodes and to ensure the treatment is safe for patients.

Participants in the study will receive the NEP-1 injection and undergo imaging with the NanoEcho Imaging Device. The study will monitor the size and distance of lymph nodes from the injection site and check for any side effects or changes in health. The goal is to improve the understanding of how rectal cancer spreads and to develop better ways to detect it early. The study is expected to continue until mid-2025.

Participants in the study will receive either Pramipexole or a placebo and will be monitored over the course of nine weeks. The maximum dosage of Pramipexole will be 3.15 milligrams per day, adjusted to avoid any intolerable side effects. The study will involve regular assessments to track changes in anhedonia symptoms and other related measures. These assessments will include questionnaires and possibly the use of activity meters to measure physical activity and sleep patterns. Additionally, some participants may undergo brain imaging techniques like fMRI to observe brain activity related to pleasure and reward.

The purpose of this study is to explore whether Pramipexole can be an effective additional treatment for reducing anhedonia in people with major depression. By comparing the effects of Pramipexole to a placebo, researchers hope to gain insights into its potential benefits and any side effects. The study is expected to continue until December 2026, with the goal of improving treatment options for those experiencing anhedonia as part of their depression.

The purpose of the study is to see how well the IVX-A12 vaccine works in preventing lung infections caused by RSV and hMPV in adults aged 60 and older. Participants in the study will receive either the IVX-A12 vaccine or a placebo, which is a substance that looks like the vaccine but does not contain the active ingredients. The study will monitor participants over a period of time to check for any signs of these infections and to assess the safety of the vaccine.

Participants will be followed through different seasons to observe the occurrence of infections. The study aims to gather information on how effective the vaccine is in preventing these infections and to ensure it is safe for use in older adults. This research is important for developing new ways to protect against these common respiratory viruses.

The purpose of the study is to see which treatment is more effective in helping patients live longer and in slowing down the progression of the cancer as seen on scans. Participants in the study will receive either Ifinatamab Deruxtecan or Docetaxel. The study will monitor how long patients live and how long it takes for the cancer to get worse. The study will also look at other factors, such as how long it takes before patients need another treatment, how the cancer responds to the treatment, and any side effects experienced by the participants.

Participants will be closely monitored throughout the study, which will include regular check-ups and scans to assess the progress of the cancer. The study aims to provide valuable information on the effectiveness and safety of Ifinatamab Deruxtecan compared to Docetaxel in treating metastatic castration-resistant prostate cancer.